Tag results:

lymphoma

Identification of NOXA as a Pivotal Regulator of Resistance to CAR T Cell Therapy in B Cell Malignancies

[Signal Transduction and Targeted Therapy] Via an unbiased genome-wide CRISPR/Cas9 screening, scientists identified loss of NOXA, a B-cell lymphoma 2 family protein in B cell malignancies, as a pivotal regulator of resistance to CAR T cell therapy by impairing apoptosis of tumor cells both in vitro and in vivo.

FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B Cell Lymphoma

[US FDA] The FDA approved axicabtagene ciloleucel for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes

[AVM Biotechnology, LLC (Business Wire)] AVM Biotechnology, LLC, announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease will allow the company to pursue additional research in the use of AVM0703 as a monotherapy and combination therapy to reverse recent onset and established Type 1 Diabetes.

Ablation of Cbl-B and C-cbl in Dendritic Cells Causes Spontaneous Liver Cirrhosis via Altering Multiple Properties of CD103+ cDC1s

[Cell Death Discovery] Scientists found that specific deletion of Cbl-b and c-Cbl in CD11c+ cells, predominantly in dendritic cells (DCs), led to liver fibrosis, cirrhosis, and accumulation of systemic conventional Type I DCs due to enhanced cell proliferation and decreased cell apoptosis.

Bioinstructive Implantable Scaffolds for Rapid In Vivo Manufacture and Release of CAR-T Cells

[Nature Biotechnology] The authors described an implantable Multifunctional Alginate Scaffold for T Cell Engineering and Release that streamlined in vivo CAR-T cell manufacturing and reduced processing time to a single day.

Durable Remission for Four Pediatric Patients with High-Risk Relapsed Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin plus Gemcitabine but without Autologous Stem Cell Transplantation:...

[Pediatric Blood & Cancer] While the majority of patients with complete responses to the brentuximab vedotin with gemcitabine regimen ultimately underwent high-dose chemotherapy and autologous stem cell transplantation (ASCT) consolidation, four subjects, reported herein, achieved durable complete remissions lasting more than four years after the study treatment but without ASCT consolidation.

Popular